Michael Hurwitz, MD, PhD

Sequencing of Agents for Castration-Resistant Prostate Cancer

November 15, 2013

Michael Hurwitz, MD, PhD
Daniel P. Petrylak, MD

In this review we will outline an approach to sequencing new therapies for metastatic castration-resistant prostate cancer (CRPC), with particular attention paid to the biology of CRPC.

READ >>
Add new comment

We've noticed that you're using an ad blocker

Our content is brought to you free of charge because of the support of our advertisers. To continue enjoying our content, please turn off your ad blocker.

It's off now Dismiss How do I disable my ad blocker?